title: A study of the efficacy of antibacterial sutures for surgical site infection: a retrospective controlled trial.
abstract: To reduce bacterial adherence to surgical sutures, triclosan-coated polyglactin 910 suture materials with antiseptic activity were developed. The aim of this study was to evaluate whether the incidence of surgical site infections can be reduced when triclosan-coated sutures are used. Until December 2009, we used conventional polyglactin 910 sutures (VICRYL, Ethicon) for the closure of the fascia in digestive tract surgery. Therefore, for the control group we retrospectively collected surveillance data for 1.5 years. In the control group, 611 patients underwent digestive tract surgery with VICRYL sutures. Beginning in July 2010, we used triclosan-coated polyglactin 910 sutures (VICRYL Plus, Ethicon, Tokyo, Japan) for the closure of the fascia in all digestive surgeries. So, we collected data for the study group from July 2010 until June 2011. In the study group, 467 patients underwent digestive tract surgery with triclosan-coated VICRYL Plus sutures. In the control group, 75 patients (12.2%) developed wound infections. In the study group, 31 patients (6.6%) developed wound infections, which was significantly lower. Emergency cases; laparoscopic cases, including some cholecystectomy and colectomy cases; American Society of Anesthesiologists classification; the use of immunosuppressive therapy; colostomy cases; wound classification; and suture material were identified as the risk factors for wound infections. In both groups, as the wound classification worsened, the wound infection rate increased. Triclosan-coated polyglactin 910 antimicrobial sutures lead to a significant decrease in the incidence of surgical site infections, especially in clean/contaminated cases.
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan.
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Hoshino
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Syu
authors.initials: S
authors.lastname: Tanimura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yamauchi
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Noritomi
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yamashita
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011098:Polyglactin 910; D012189:Retrospective Studies; D012307:Risk Factors; D013530:Surgical Wound Infection / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D013537:Sutures; D016896:Treatment Outcome; D014260:Triclosan / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D011098:Polyglactin 910; D014260:Triclosan